Compare Recursion Pharmaceuticals Inc (RXRX) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Utilities Select Sector SPDR Fund — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while Utilities Select Sector SPDR Fund trades at $43.07. The key difference: Utilities Select Sector SPDR Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | XLU | |
|---|---|---|
Market Cap | $1.86B | — |
Sector | Health | — |
52-Week High | $6.79 | $47.73 |
52-Week Low | $2.84 | $41.86 |
Enterprise Value | $1.38B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
XLU trades at $43.45, up 0.86% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The utilities ETF faces conflicting narratives around AI power demand versus regulatory headwinds, with recent news highlighting both defensive appeal and concerns about concentrated AI exposure. Support levels cluster around $42-43 while resistance sits at $44.
The ETF's outlook balances defensive utility characteristics against AI-driven growth potential. Key opportunities include inflation hedging and dividend income, while risks center on regulatory intervention and uneven AI benefits across the portfolio. Current sentiment reflects cautious optimism as investors weigh utility stability against transformative power demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
